CYBN
Price
$7.55
Change
-$0.04 (-0.53%)
Updated
Aug 8, 10:30 AM (EDT)
Capitalization
178.71M
EYPT
Price
$10.08
Change
+$0.01 (+0.10%)
Updated
Aug 8, 10:31 AM (EDT)
Capitalization
692.93M
82 days until earnings call
Interact to see
Advertisement

CYBN vs EYPT

Header iconCYBN vs EYPT Comparison
Open Charts CYBN vs EYPTBanner chart's image
Cybin
Price$7.55
Change-$0.04 (-0.53%)
Volume$643
Capitalization178.71M
EyePoint Pharmaceuticals
Price$10.08
Change+$0.01 (+0.10%)
Volume$1K
Capitalization692.93M
CYBN vs EYPT Comparison Chart in %
Loading...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYBN vs. EYPT commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYBN is a Hold and EYPT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (CYBN: $7.59 vs. EYPT: $10.07)
Brand notoriety: CYBN and EYPT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYBN: 69% vs. EYPT: 107%
Market capitalization -- CYBN: $178.71M vs. EYPT: $692.93M
CYBN [@Biotechnology] is valued at $178.71M. EYPT’s [@Biotechnology] market capitalization is $692.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYBN’s FA Score shows that 1 FA rating(s) are green whileEYPT’s FA Score has 1 green FA rating(s).

  • CYBN’s FA Score: 1 green, 4 red.
  • EYPT’s FA Score: 1 green, 4 red.
According to our system of comparison, EYPT is a better buy in the long-term than CYBN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYBN’s TA Score shows that 2 TA indicator(s) are bullish while EYPT’s TA Score has 3 bullish TA indicator(s).

  • CYBN’s TA Score: 2 bullish, 6 bearish.
  • EYPT’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, EYPT is a better buy in the short-term than CYBN.

Price Growth

CYBN (@Biotechnology) experienced а -1.30% price change this week, while EYPT (@Biotechnology) price change was +2.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

EYPT is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($693M) has a higher market cap than CYBN($179M). EYPT YTD gains are higher at: 35.168 vs. CYBN (-13.946). CYBN has higher annual earnings (EBITDA): -134.52M vs. EYPT (-144.55M). EYPT has more cash in the bank: 318M vs. CYBN (136M). CYBN has less debt than EYPT: CYBN (0) vs EYPT (24.1M). EYPT has higher revenues than CYBN: EYPT (56M) vs CYBN (0).
CYBNEYPTCYBN / EYPT
Capitalization179M693M26%
EBITDA-134.52M-144.55M93%
Gain YTD-13.94635.168-40%
P/E RatioN/AN/A-
Revenue056M-
Total Cash136M318M43%
Total Debt024.1M-
FUNDAMENTALS RATINGS
CYBN vs EYPT: Fundamental Ratings
CYBN
EYPT
OUTLOOK RATING
1..100
5962
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
9488
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6238
P/E GROWTH RATING
1..100
10018
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYBN's Valuation (18) in the null industry is somewhat better than the same rating for EYPT (60) in the Pharmaceuticals Major industry. This means that CYBN’s stock grew somewhat faster than EYPT’s over the last 12 months.

EYPT's Profit vs Risk Rating (88) in the Pharmaceuticals Major industry is in the same range as CYBN (94) in the null industry. This means that EYPT’s stock grew similarly to CYBN’s over the last 12 months.

EYPT's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as CYBN (97) in the null industry. This means that EYPT’s stock grew similarly to CYBN’s over the last 12 months.

EYPT's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as CYBN (62) in the null industry. This means that EYPT’s stock grew similarly to CYBN’s over the last 12 months.

EYPT's P/E Growth Rating (18) in the Pharmaceuticals Major industry is significantly better than the same rating for CYBN (100) in the null industry. This means that EYPT’s stock grew significantly faster than CYBN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYBNEYPT
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 16 days ago
79%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DQJCY36.190.25
+0.70%
Pan Pac Intl Hldgs Corp.
JTTRY15.34N/A
N/A
Japan Airport Terminal
PPZRF0.01N/A
N/A
SEASIF EXPLORATION INC.
IDGAF0.08N/A
N/A
5TH PLANET GAMES
KNMOF18.13N/A
N/A
Kanamoto Co Ltd.

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
+1.74%
ATAI - CYBN
42%
Loosely correlated
-0.95%
RXRX - CYBN
35%
Loosely correlated
-1.28%
ABSI - CYBN
33%
Loosely correlated
+0.34%
EYPT - CYBN
30%
Poorly correlated
-4.82%
ABCL - CYBN
29%
Poorly correlated
+2.67%
More

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with OCUL. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
-4.82%
OCUL - EYPT
63%
Loosely correlated
-1.60%
LYRA - EYPT
58%
Loosely correlated
+1.62%
RXRX - EYPT
54%
Loosely correlated
-1.28%
BEAM - EYPT
54%
Loosely correlated
-2.40%
ATHE - EYPT
54%
Loosely correlated
+3.11%
More